FAIM
GTHX

Financial Advocates Investment Management’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Financial Advocates Investment Management’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-14,450
Closed -$62.4K – 841
2024
Q1 		$62.4K Buy
14,450
+1,500
+12% +$5.23K ﹤0.01% 749
2023
Q4 		$39.5K Buy
+12,950
New +$24.3K ﹤0.01% 718

Other funds holding GTHX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Financial Advocates Investment Management's GTHX Position: Q2 2024 in Review

Financial Advocates Investment Management sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2024, closing a stake of 14,450 shares — an estimated $62.4K sold.

Financial Advocates Investment Management first reported a position in GTHX in Q4 2023 and held it in 2 quarters. The position peaked at $62.4K in Q1 2024. 88 funds tracked by Wall St. Rank hold GTHX as of Q2 2024.

  • Financial Advocates Investment Management reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Financial Advocates Investment Management sold 14,450 G1 Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $62.4K.
  • Financial Advocates Investment Management first reported a position in G1 Therapeutics, Inc. Common Stock in Q4 2023 and held it in 2 quarters.
  • Financial Advocates Investment Management's G1 Therapeutics, Inc. Common Stock position peaked at $62.4K in Q1 2024.
  • 88 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Financial Advocates Investment Management's 13F filing for Q2 2024, filed 29 Jul 2024.